Free Trial
NASDAQ:DWTX

Dogwood Therapeutics (DWTX) Stock Price, News & Analysis

Dogwood Therapeutics logo
$6.47 +0.14 (+2.21%)
Closing price 03/24/2025 04:00 PM Eastern
Extended Trading
$6.28 -0.19 (-3.01%)
As of 09:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dogwood Therapeutics Stock (NASDAQ:DWTX)

Key Stats

Today's Range
$5.88
$6.73
50-Day Range
$1.87
$17.40
52-Week Range
$1.62
$29.28
Volume
269,995 shs
Average Volume
1.99 million shs
Market Capitalization
$8.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Remove Ads
Receive DWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DWTX Stock News Headlines

FY2024 Earnings Estimate for DWTX Issued By Zacks Small Cap
Dogwood doses first patient in Phase 2b trial of Halneuron
“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
Maxim Group Remains a Buy on Dogwood Therapeutics (DWTX)
See More Headlines

DWTX Stock Analysis - Frequently Asked Questions

Dogwood Therapeutics' stock was trading at $2.49 at the beginning of 2025. Since then, DWTX stock has increased by 159.8% and is now trading at $6.47.
View the best growth stocks for 2025 here
.

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.33) by $0.72.

Dogwood Therapeutics's stock reverse split on the morning of Wednesday, October 9th 2024. The 1-25 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional investors of Dogwood Therapeutics include Geode Capital Management LLC (0.82%) and Concourse Financial Group Securities Inc..

Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/07/2024
Today
3/24/2025
Next Earnings (Estimated)
3/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DWTX
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.94 per share
Price / Book
1.31

Miscellaneous

Free Float
1,169,000
Market Cap
$8.62 million
Optionable
N/A
Beta
2.07
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DWTX) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners